Australia Registers Inhaler Device for Medical Cannabis Liquid Extracts

Australia's Therapeutic Goods Administration has registered the QMID, an inhaler device for medical cannabis liquid extracts, following an announcement by Curaleaf. The device functions with compatible cartridges and expands the range of approved delivery options for patients in Australia's medical cannabis program. This registration represents progress in standardizing cannabis administration methods, though device approval does not automatically authorize all medications for use with the inhaler. The development reflects growing regulatory recognition of inhalation as a viable delivery route for cannabinoid therapeutics, potentially offering patients more precise dosing and faster onset compared to other administration methods.